Novo Nordisk's share plunges 19.5% post release of weight loss drug CagriSema's trial results Company Business News Novo Nordisk announces positive results for CagriSema in type 2 diabetes PMLiVE CagriSema is a fixed dose combination of a long acting amylin analogue, cagrilintide 2.4 mg and Novo Nordisk's blockbuster obesity drug, Wegovy (semaglutide 2.4 mg). The two molecules promote weight loss by suppressing hunger, Novo Next Generation Obesity Shot Falls Short of Lilly Rival Bloomberg Novo Nordisk presents phase 3 data for next generation amylin cagrilintide, leading to advancement into dedicated clinical programme Weight loss: New drug CagriSema leads to 14% weight loss in trial
Shopping security
Each payment you make on thelockerguy is secured with strict SSL encryption and PCI DSS data protection protocols
product description
Why choose thelockerguy wholesale?
Show More
cagrilintide novo nordisk Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug